tirzepatide surpass 2 versus insulin glargine as second-line or third-line therapy in type diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial SURPASS-CVOT: Tirzepatide Significantly Reduces Major

Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW

But it is a powerful, evidence-based tool for people who want: Appetite control without injections Weight loss without hormone manipulation A natural alternative to GLP-1 medications A sustainable, habit-based solution And most importantly: guidance from a clinician who looks at your whole health, not just the scale

Al Balwi R, Al Madani W, Al Ghamdi A

The GIC provides insurance for more than 460,000 public employees and retirees, and the agency is poised to receive a $300 million funding infusion to ensure it can continue to pay claims after April

Mood changes, particularly increased irritability or low mood

Cautions: Keep out of reach of children